Less Ads, More Data, More Tools Register for FREE

Pin to quick picksLitigation Cap. Regulatory News (LIT)

Share Price Information for Litigation Cap. (LIT)

Share Price is delayed by 15 minutes
Get Live Data
2.60    -0.10 (-3.70%)
Bid:
2.50
Ask:
2.60
Spread: 0.10 (4.00%)
Market Cap: £2.68m
LIT Live PriceLast checked at - London Stock Exchange

Intraday Litigation Cap. Share Chart

LCM Global Alternative Returns Fund II

14 Oct 2021 07:00

RNS Number : 0187P
Litigation Capital Management Ltd
14 October 2021
Β 

14 October 2021

Β 

Litigation Capital Management Limited

(LCM or the Company)

Β 

LCM completes US$200m first close of LCM Global Alternative Returns Fund II (Fund II)

with target of US$300m

Β 

Β 

Litigation Capital Management Limited (AIM:LIT), a leading international alternate asset manager of disputes financing solutions, is pleased to announce the first close of a second third-party fund, Fund II. In accordance with the Company's strategy and as previously communicated to the market, the close of Fund II accelerates our asset management strategy, managing third-party funds. With a target of US$300 million, total Assets Under Management (AUM) for LCM is expected to reach US$450 million on final close. This supplements the Company's balance sheet capital and allows us to expand and diversify our portfolio under management.

Β 

First close of Fund II is predominantly underpinned by existing investors in LCM Global Alternative Returns Fund (Fund I), which comprises a large endowment of a US University and the asset management division of a large global investment bank. Both have extensive experience of investing in the litigation finance asset class.

Structure

The Fund II structure is very similar to Fund I and is detailed as follows:

Β· Fund II will co-invest with investments from LCM's balance sheet on a 75:25 basis

Β· LCM's balance sheet contribution (25%) will be invested and advanced on a monthly basis over the term of each investment, no upfront contribution is required

Β· Performance fees will be payable to LCM as fund manager on the basis of a deal-by-deal waterfall

Β· In addition to receiving its 25% share of any profit from each direct investment from its co-investment, the fund will pay performance fees to LCM as fund manager as follows:

-25% of profit on each Fund II investment as and when it matures over a soft return hurdle (full catch up) of 8%; and

-an outperformance return of 35% for all Fund II returns which achieve a return over an IRR of 20%

Β· Fund II has a term of six years including a commitment period of two years during which investments can be entered into (theΒ Inception Period)

Fund II, as with Fund I, will target global dispute finance investments including both single disputes and corporate portfolio transactions.

At first close Fund II has raised US$200 million, leaving a balance of up to US$100 million to be raised in the subsequent months. The combination of the pace of committing Fund I, which is currently at 91%, a pipeline of quality investments and strong support from existing investors, meant LCM was well placed to commence the raise of a second fund and complete a first close.

Patrick Moloney, CEO of LCM, commented: "We are very pleased with the progress in terms of commitments for Fund I which have now reached 91%, particularly as this level of commitment has been achieved in markets which have experienced considerable disruption from COVID.

Achieving such a significant first close of Fund II is a major milestone and achievement for LCM. We were delighted at the endorsement from all existing investors in our first fund, who are predominantly participating for increased commitments in our second fund, demonstrating both investor commitment and confidence in LCMs attractive investment proposition. The first close of Fund II enables LCM to accelerate its growth strategy and provides us with increased flexibility of capital to allocate into markets which are very conducive to the litigation finance industry."

Β 

Enquiries

Litigation Capital Management

c/o Alma PRΒ 

Patrick Moloney, Chief Executive Officer

Canaccord (Nomad and Joint Broker)Β 

Tel: 020 7523 8000

Bobbie Hilliam

Investec Bank plc (Joint Broker)

Tel: 020 7597 5970

David Anderson

Alma PR

Tel:Β 020 3405 0205

Justine James

lcm@almapr.co.uk

Kieran Breheny

Molly Gretton

Β 

NOTES TO EDITORS

Β 

Litigation Capital Management (LCM) is an alternate asset manager specialising in disputes financing solutions internationally, which operates two business models. The first is direct investments made from LCM's permanent balance sheet capital and the second is third party fund management. Under those two business models, LCM currently pursues three investment strategies: Single-case funding, Portfolio funding and Acquisitions of claims. LCM generates its revenue from both its direct investments and also performance fees through asset management.

LCM has an unparalleled track record driven by disciplined project selection and robust risk management.

Currently headquartered in Sydney, with offices in London, Singapore, Brisbane and Melbourne, LCM listed on AIM in December 2018, trading under the ticker LIT.

www.lcmfinance.com

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
MSCEAFEDFAFFFAA
Date   Source Headline
1st Jun 20267:00 amRNSUpdate on Covenant Waiver, Case & Strategic Review
15th Apr 20267:30 amRNSCovenant Waiver Extension
31st Mar 20267:00 amRNSInterim results for the HY ended 31 December 2025
25th Mar 20267:00 amRNSNotice of H1 Results, Trading update and IMC
17th Mar 20267:00 amRNSJudgment Delivered in Commercial Litigation Claim
17th Mar 20267:00 amRNSJudgment Delivered in Commercial Litigation Claim
11th Mar 20269:34 amRNSUpdate on Case Investment and Strategic Review
2nd Mar 20267:00 amRNSCovenant Waiver Extension
2nd Feb 20267:00 amRNSIncrease in Credit Facility and Waiver Extension
12th Jan 20262:07 pmRNSPositive development on case
30th Dec 20257:00 amRNSCovenant Waiver Extension
30th Dec 20257:00 amRNSCovenant Waiver Extension
24th Dec 20257:00 amRNSAdverse Costs Order in Class Action Investment
27th Nov 20251:08 pmRNSResults of AGM
26th Nov 20255:00 pmRNSStrategic Review Update
19th Nov 202511:54 amRNSPosting of Annual Report and Accounts
4th Nov 20252:29 pmRNSNotice of Annual General Meeting
21st Oct 202511:37 amRNSPostponement of Annual General Meeting
13th Oct 202511:39 amRNSExercise of Awards
6th Oct 20257:00 amRNSUpdate on Commercial Arbitration Loss
2nd Oct 20258:40 amRNSTR-1
1st Oct 20254:49 pmRNSNotice of Annual General Meeting
1st Oct 202511:25 amRNSJudgment Delivered in Commercial Litigation Claim
1st Oct 20257:00 amRNSAnnual Results for the year ended 30 June 2025
15th Sep 20257:00 amRNSClass Action Investment and Strategic Review
8th Sep 20257:00 amRNSNotice of Results
23rd Jun 20259:45 amRNSTR - 1
19th Jun 20257:00 amRNSJudgment in Funded Case and Trading Update
13th May 20252:50 pmRNSStatement Regarding Media Speculation
1st Apr 20257:00 amRNSOutcome of Commercial Arbitration Investment
18th Mar 20257:00 amRNSInterim results for the HY ended 31 December 2024
7th Mar 20252:54 pmRNS-RInvestor Presentation via Investor Meet Company
28th Feb 20257:00 amRNSAppeal Filed in Class Action Investment
21st Feb 20257:00 amRNSJudgment Delivered in Class Action Investment
4th Feb 20258:33 amRNSHolding(s) in Company
29th Jan 20257:00 amRNSTrading Update
15th Jan 202511:14 amRNSHolding(s) in Company
19th Dec 20247:00 amRNSDirectorate Change
6th Dec 202411:15 amRNSHolding(s) in Company
6th Dec 20247:00 amRNSAppointment of CFO to the Board of Directors
4th Dec 20247:00 amRNSJudgment Delivered in Class Action Investment
2nd Dec 20247:00 amRNSNew Credit Facility
15th Nov 20247:00 amRNSDirector/PDMR Shareholding
8th Nov 20247:06 amRNSHolding(s) in Company
8th Nov 20247:00 amRNSTransaction in Own Shares
7th Nov 20247:00 amRNSTransaction in Own Shares
6th Nov 20247:00 amRNSTransaction in Own Shares
5th Nov 20247:00 amRNSTransaction in Own Shares
4th Nov 20247:00 amRNSTransaction in Own Shares
1st Nov 20247:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.